Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
This triple-action approach enhances metabolism, suppresses appetite, and has shown potential for even greater weight loss outcomes than its predecessors
The progression: mono dual triple The clinical progression across incretin agonists illustrates the rationale, using reported trial weight-reduction figures as the anchor: Semaglutide (mono-agonist): ~15% body-weight reduction in Phase 3 trials Tirzepatide (dual agonist): ~22% body-weight reduction in Phase 3 trials Retatrutide (triple agonist): ~24% in Phase 2, and ~28% at the highest dose in the Phase 3 TRIUMPH-1 obesity readout (2026) Each generation extended the effects of the previous, with the triple agonist at the current frontier
Affordability and access remain the dividing lines between those who can benefit from these medications and those who cannot
"It's possible to have fluctuations in your thyroid hormone, which is another big heat regulator in the body as well." When your thyroid gland produces less thyroid hormone, you might feel cold
A 10mg vial, 2mL of bacteriostatic water, a U-100 insulin syringe
To find the dose per unit, you divide: 10,000 mcg / 100 units = 100 mcg per unit
